Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 650 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $25.39, for a total value of $16,503.50. Following the completion of the transaction, the insider owned 21,479 shares in the company, valued at approximately $545,351.81. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Castle Biosciences Stock Down 2.7%

Castle Biosciences stock opened at $25.00 on Friday. The stock has a market cap of $743.28 million, a PE ratio of -29.41 and a beta of 1.09. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.11 and a current ratio of 5.26. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The stock has a fifty day moving average of $33.22 and a 200 day moving average of $31.70.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.15. The business had revenue of $81.88 million for the quarter, compared to analysts’ expectations of $81.19 million. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%. As a group, sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Institutional Investors Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Castle Biosciences by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after purchasing an additional 27,511 shares during the period. RTW Investments LP bought a new stake in shares of Castle Biosciences during the 4th quarter valued at $82,283,000. Principal Financial Group Inc. lifted its stake in shares of Castle Biosciences by 0.7% during the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock valued at $70,317,000 after buying an additional 13,289 shares in the last quarter. Portolan Capital Management LLC lifted its stake in shares of Castle Biosciences by 1.7% during the 3rd quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock valued at $34,499,000 after buying an additional 25,539 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Castle Biosciences by 7.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock worth $33,564,000 after buying an additional 96,084 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on CSTL shares. Robert W. Baird boosted their target price on shares of Castle Biosciences from $41.00 to $44.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Lake Street Capital lifted their price target on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Guggenheim boosted their price objective on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. Finally, Morgan Stanley raised Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.57.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.